<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In auto-<z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory diseases</z:e>, the role of the inflammasome and the interleukine IL-1beta has recently been shown </plain></SENT>
<SENT sid="1" pm="."><plain>Thus, the physiopathology of <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare diseases</z:e> as Cryopyrin-associated <z:e sem="disease" ids="C0585274" disease_type="Disease or Syndrome" abbrv="">periodic syndrome</z:e> (CAPS) is better understood </plain></SENT>
<SENT sid="2" pm="."><plain>In the era of biologics, new treatments targeting IL-1 have been developped </plain></SENT>
<SENT sid="3" pm="."><plain>Canakinumab is a fully humanized monoclonal antibody inhibiting specifically IL-1beta Clinical studies have shown its efficacy on clinical symptoms and on inflammatory markers in patients with <z:e sem="disease" ids="C0678236" disease_type="Disease or Syndrome" abbrv="">rare diseases</z:e> such as CAPS or idiopathic juvenile <z:hpo ids='HP_0001369'>arthritis</z:hpo>, but also in more common rheumatic conditions like <z:hpo ids='HP_0001997'>gout</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Canakinumab has been approved in Switzerland only for the treatment of CAPS </plain></SENT>
<SENT sid="5" pm="."><plain>Studies evaluating its effect on <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular diseases</z:e> are ongoing </plain></SENT>
</text></document>